FIBROGEN INC — Director's Dealing 2016

Mar 4, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FIBROGEN INC (FGEN)
CIK: 0000921299
Period of Report: 2016-03-01

Reporting Person: VALONE FRANK H MD (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-01	Common Stock	M	6528	$3.925	Acquired	115133	Direct
2016-03-01	Common Stock	M	2508	$2.90	Acquired	117641	Direct
2016-03-01	Common Stock	M	1714	$3.50	Acquired	119355	Direct
2016-03-01	Common Stock	S	7260	$16.471	Disposed	112095	Direct
2016-03-01	Common Stock	S	3490	$17.6106	Disposed	108605	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-01	Stock Option (Right to Buy)	$3.925	M	6528	Disposed	2019-08-11	Common Stock (6528)	Direct
2016-03-01	Stock Option (Right to Buy)	$2.90	M	2508	Disposed	2020-06-09	Common Stock (2508)	Direct
2016-03-01	Stock Option (Right to Buy)	$3.50	M	1714	Disposed	2021-06-07	Common Stock (1714)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4000	Indirect

Footnotes

F1: Shares sold pursuant to a 10b5-1 plan.

F2: The shares were sold at prices between $16.02 and $17.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares were sold at prices between $17.02 and $17.98. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: Fully vested.